|View printer-friendly version|
|January 28, 2005 9:54 a.m.|
|Teva Announces Approval Of Glyburide/Metformin Hcl Tablets|
Jerusalem, Israel, January 28, 2005 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has granted final approval for the company's ANDA for Glyburide and Metformin HCl Tablets, 1.25 mg/250 mg, 2.5 mg/500 mg and 5 mg/500 mg. Shipment of this product is expected to begin shortly.